International Edition
Latest News
Health

Flu Vaccine Effectiveness Median 39.5% Over 18 Seasons, Below 40-60% Benchmark

A study of 18 U.S. flu seasons from 2004–2005 through 2023–2024 found a median vaccine effectiveness of 39.5%, below the 40% to 60% benchmark cited by the CDC and WHO. The study examined 18 influenza seasons from 2004–2005…

Flu Vaccine Effectiveness Median 39.5% Over 18 Seasons, Below 40-60% Benchmark

A study of 18 U.S. flu seasons from 2004–2005 through 2023–2024 found a median vaccine effectiveness of 39.5%, below the 40% to 60% benchmark cited by the CDC and WHO.

The study examined 18 influenza seasons from 2004–2005 through 2023–2024 using data from the U.S, according to Mdtoday.

Flu VE Network. The median vaccine effectiveness against medically attended influenza was 39.5%, below the lower bound of the long-standing benchmark. Effectiveness varied widely by season, with a 95% prediction interval for any single future season spanning approximately 16% to 59%.

Antigenic mismatch between the vaccine strains and circulating viruses occurred in 11 of the 18 seasons, or roughly 61% of the time, the researchers found. The 40% to 60% figure often referenced by the Centers for Disease Control and Prevention and the World Health Organization reflects performance when the match is good, not the average across all years, the authors said.

The analysis measured reductions in outpatient visits for laboratory-confirmed influenza. It did not assess protection against hospitalization or death, which studies consistently show is higher. The CDC estimated that vaccination prevented 9.8 million illnesses, 120,000 hospitalizations, and 7,900 deaths during the 2023–2024 season alone.

Ortiz said the findings argue for more transparent communication about expected performance and for continued investment in broadly protective vaccines that are less dependent on annual strain selection.

How the study was conducted

Researchers pooled adjusted vaccine effectiveness estimates from the U.S. Flu VE Network for each season. They compared those estimates against whether the World Health Organization characterized the season’s dominant viruses as antigenically similar to the vaccine components. The median of the 18 point estimates was 39.5%. The prediction interval was derived from the observed between-season variance.

Mismatch drives the gap

In seasons with good antigenic match, effectiveness clustered near the 50% to 60% range. In mismatched seasons, estimates frequently dropped below 30%. The 2014–2015 season, dominated by a drifted H3N2 clade, recorded effectiveness of 19%. The 2022–2023 season, also marked by H3N2 mismatch, reached 42%.

Why the benchmark persists

Public health agencies have used the 40% to 60% range for years to set expectations and support vaccination campaigns. The CDC’s current website states that recent studies show the vaccine reduces the risk of flu illness by between 40% and 60% among the overall population during seasons when most circulating viruses are well-matched to the vaccine.

The Maryland team argued that quoting the conditional range without emphasizing how often mismatch occurs can erode trust when effectiveness comes in lower. They recommended presenting both the average performance and the full distribution of past results.

Protection against severe outcomes remains strong

While the study focused on outpatient visits, the authors emphasized that vaccination consistently reduces hospitalizations and deaths even in low-effectiveness years. A 2022 CDC study found that vaccination reduced the risk of flu-related ICU admission by 26% and death by 31% among adults, with higher protection against severe outcomes in children.

Limitations

The analysis relied on U.S. data and test-negative design estimates, which may not generalize to all populations or vaccine products. Effectiveness can differ by age group, vaccine type, and prior immunity. The prediction interval reflects historical variability, not a forecast for any specific upcoming season.

What this means for the next shot

The findings do not support changing vaccination recommendations. The CDC continues to recommend annual vaccination for everyone six months and older. The authors called for accelerated development of universal or broadly reactive influenza vaccines that could deliver more consistent protection regardless of antigenic drift.

“Understanding the real-world performance of current vaccines is essential to maintaining public confidence and guiding better vaccine design,” Ortiz said.

Flu vaccine effectiveness: key figures at a glance

Metric Value Context
Median effectiveness (18 seasons) 39.5% Against medically attended, lab-confirmed flu
95% prediction interval (single season) 16% – 59% Reflects year-to-year variability
Seasons with antigenic mismatch 11 of 18 (61%) WHO characterization of circulating vs. vaccine strains

Flu vaccine still prevents severe outcomes despite lower effectiveness

Does this study mean the flu shot doesn’t work?
No. The vaccine still prevents millions of illnesses and tens of thousands of hospitalizations each year. The study shows that protection against mild or moderate illness severe enough to prompt a doctor visit is lower on average than the often-cited 40% to 60% range, but protection against severe outcomes remains substantial.

Why is the flu vaccine less effective some years?
The vaccine is reformulated annually based on predictions made months in advance. Circulating viruses can mutate after the strains are selected, or a different strain can dominate than expected. This antigenic mismatch occurred in 11 of the last 18 seasons.

Should I still get vaccinated this year?
Yes. The CDC and the study authors both recommend annual vaccination. Even when effectiveness against infection is modest, the vaccine significantly lowers the risk of hospitalization and death.

What is a “prediction interval” and why does it matter?
A prediction interval shows the range where a single future observation is likely to fall based on past variability. The 16% to 59% interval means that in any given season, effectiveness could be quite low or moderately high, underscoring the uncertainty of relying on a single point estimate.

The Centers for Disease Control and Prevention, founded July 1, 1946 as the Communicable Disease Center, succeeded a World War II malaria control program and chose Atlanta as its headquarters because malaria was endemic in the Southern United States. With an initial budget of about $1 million, 59 percent of its 369 employees worked on mosquito abatement, spraying more than six and a half million homes, mostly with DDT, in its early years.

The agency created the Epidemic Intelligence Service in 1951 after its chief epidemiologist warned of potential biological warfare during the Korean War, establishing a two-year postgraduate training program that later expanded globally. In 1947, CDC employees collected funds to purchase 15 acres on Clifton Road from Emory University for $10, land that remains the site of its headquarters today.

Are new flu vaccines in development that could solve the mismatch problem? Researchers are pursuing broadly protective or “universal” influenza vaccines that target conserved parts of the virus.

About the author: Health Desk

Health Desk at Archynewsy.